▲ Peaking
Business
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is acquiring UK-based Myricx Bio in a deal valued at up to $1.5 billion to expand its cancer-drug pipeline.
3 trends tracked about this subject — the full history, oldest to newest below.
Novartis is acquiring UK-based Myricx Bio in a deal valued at up to $1.5 billion to expand its cancer-drug pipeline.
French biotech company Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion to expand its blood cancer pipeline.
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.